IL-28A CRISPR/Cas9 KO Plasmid (h): sc-405375
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IL-28A CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the IL-28A genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IL-28A CRISPR/Cas9 KO Plasmid (h) | sc-405375 | 20 µg | $397.00 |
Overview
IFNL2 encodes interferon lambda 2 (IL-28A), a type III interferon that signals through the IFNLR1/IL10RB receptor complex to activate JAK–STAT pathways and induce interferon-stimulated genes. This cytokine supports epithelial and mucosal antiviral defense and modulates innate and adaptive immune responses by shaping chemokine production and antigen presentation. IL-28A activity intersects with pattern-recognition receptor signaling, including TLR and RIG-I-like receptor pathways, to coordinate antiviral transcriptional programs. Dysregulated IFNL2 signaling and genetic variation have been associated with differential outcomes in viral infection and inflammatory processes, making it a useful target for mechanistic studies of host–pathogen interactions and immune regulation.
IL-28A CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the IFNL2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the IFNL2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the IFNL2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish IL-28A protein expression.
This CRISPR knockout system enables efficient generation of IFNL2-deficient cell models for investigation of IL-28A signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting IFNL2 exon(s) critical for IL-28A function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple IFNL2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by IL-28A CRISPR/Cas9 KO Plasmid (h) and IL-28A CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the IFNL2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by IL-28A HDR Plasmid (h) and IL-28A HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by IFNL2 homology arms to support homology-directed repair at defined IFNL2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.